✉news ScienceSpace Policy first seen 19 h ago, last 18 h ago, peak #33

Biosimilars Sector Poised for M&A Shake-Up as Patent Cliff Looms

Original: Biosimilars at an Inflection Point: How Regulatory Reform, a Maturing Patent Framework and a Looming Patent Cliff Are Reshaping M&A

Legal and industry analysts say the biosimilars market has reached an inflection point, with regulatory reform, a maturing patent litigation framework and an approaching wave of major biologic patent expirations reshaping merger and acquisition strategy. Commentators expect pharmaceutical companies to pursue deals to capture market share as blockbuster biologics lose exclusivity and cheaper biosimilar competition intensifies.

Why now: A looming patent cliff is expected to trigger a wave of biosimilar-related deals, drawing attention from pharma and legal circles.

biosimilars industrypharmaceutical companiesJD Supra

Open on news →

Rank over time, top of the chart is #1. 2 snapshots from 19 h ago to 18 h ago.

Evidence

• Biosimilars at an Inflection Point: How Regulatory Reform, a Maturing Patent Framework and a Looming Patent Cliff Are Reshaping M&A · JD Supra

API: https://socialmediatrends-api.osmike.com/v1/trends/4626